New Drug Information Website

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD, and Yesne Alici, MD, will utilize decision-making capacity techniques.

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

American Society for Transplantation and Cellular Therapy

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.

Michael Barish, PhD

November 17th 2025

Immune Priming Strategies Numerically Improve PFS in Ovarian Cancer

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Non-Viral Gene Therapy Displays Feasibility in EGFR-Mutated NSCLC

Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

How Does Decision-Making Capacity, Patient-Centered Care Inform Oncology Decisions?

No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

Related Content

Ariana Pelosci

November 25th 2025

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD, and Yesne Alici, MD, will utilize decision-making capacity techniques.

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

American Society for Transplantation and Cellular Therapy

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.

Michael Barish, PhD

November 17th 2025

Immune Priming Strategies Numerically Improve PFS in Ovarian Cancer

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Non-Viral Gene Therapy Displays Feasibility in EGFR-Mutated NSCLC

Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.